{"id":"NCT04599972","sponsor":"Orasis Pharmaceuticals Ltd.","briefTitle":"An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-2)","officialTitle":"A Multi-Center, Double-Masked, Vehicle-Controlled, Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (the NEAR-2 Study: Near Eye-vision Acuity Restoration)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-10-26","primaryCompletion":"2022-01-21","completion":"2022-01-28","firstPosted":"2020-10-23","resultsPosted":"2023-11-28","lastUpdate":"2024-04-04"},"enrollment":304,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Presbyopia"],"interventions":[{"type":"DRUG","name":"CSF-1","otherNames":["pilocarpine HCl 0.4%"]},{"type":"DRUG","name":"Vehicle","otherNames":[]}],"arms":[{"label":"CSF-1","type":"EXPERIMENTAL"},{"label":"Vehicle","type":"PLACEBO_COMPARATOR"}],"summary":"This is a 4-visit, multi-center, randomized, double-masked, vehicle-controlled study evaluating the safety and efficacy of CSF-1 in the temporary correction of presbyopia.","primaryOutcome":{"measure":"Percentage of Subjects With a ≥ 3-line Gain in BDCVA (Best Distance-Corrected Visual Acuity) at 40cm and no Loss in BDCVA ≥ 5 Letters at 4m on Day 8, 1 Hour Post-Dose 1.","timeFrame":"Baseline (Day 1) to Day 8 (1 hour post-Dose 1)","effectByArm":[{"arm":"CSF-1","deltaMin":64,"sd":null},{"arm":"Vehicle","deltaMin":32,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.01"}]},"eligibility":{"minAge":"45 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":18,"countries":["United States"]},"refs":{"pmids":["38216351"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":153},"commonTop":["headache","vision blurred","instillation site pain"]}}